Host |
Mouse |
Klon |
D2-40 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
7 ml |
Ready-to-use |
CE/IVD |
Z2097MP |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
1:20 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
0.5 ml |
Concentrate |
CE/IVD |
Z2097MS |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Germ cell tumor. |
Verdünnung |
1:20 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
M2A |
Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
0.1 ml |
Concentrate |
CE/IVD |
Z2097MT |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lymphendothelium |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Diagnostic Biosystems |
D2-40 |
6 ml |
Ready-to-use |
CE/IVD |
PDM558 |
-
|
Host |
Mouse |
Klon |
D2-40 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lymphendothelium |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Diagnostic Biosystems |
D2-40 |
25 ml |
Ready-to-use |
CE/IVD |
PDM558-25 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
1 ml |
Concentrate |
CE/IVD |
Z2338ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
7 ml |
Ready-to-use |
CE/IVD |
Z2338MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
0.5 ml |
Concentrate |
CE/IVD |
Z2338MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Mesothelioma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
0.1 ml |
Concentrate |
CE/IVD |
Z2338MT |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma, testis |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3252A |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma, testis |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3252B |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3252G7 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Biocare Medical |
EPR20330 |
6 ml |
Ready-to-use |
CE/IVD |
API3252AA |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus, Cytoplasma membrane |
PRAME
|
Zytomed Systems GmbH |
EPR20330 |
6 ml |
ready-to-use |
RUO |
RBG073 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus, Cytoplasma membrane |
PRAME
|
Zytomed Systems GmbH |
EPR20330 |
0.5 ml |
Concentrate |
RUO |
RBK073-05 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
1 ml |
Concentrate |
CE/IVD |
RMAB109 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB109-01 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB109-05 |
-
|
Host |
Rabbit |
Klon |
EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment within Human PRAME aa 100 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Nucleus, cell membrane |
PRAME
|
Diagnostic Biosystems |
EPR20330 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD109 |
-
|
Host |
Mouse |
Klon |
2G11 |
Format |
Purified |
Methode |
EL, P |
Vorbehandlung |
Citrate |
Isotyp |
Mouse IgG2a |
Verdünnung |
Synthetic peptide 146-R (154) R (171) -182 of ovine PrP |
Prion Protein (PrP, CD230)
|
Zytomed Systems GmbH |
2G11 |
250 µg |
Purified |
RUO |
616-0195 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 -1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
1 ml |
Concentrate |
CE/IVD |
RMAB002 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB002-01 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB002-05 |
-
|
Host |
Rabbit |
Klon |
SP2 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA pH8 |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Diagnostic Biosystems |
SP2 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD002 |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:200 - 1:400 |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
1.0 ml |
Concentrate |
CE/IVD |
Z2023RL |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2023RP |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:200 - 1:400 |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2023RS |
-
|
Host |
Rabbit |
Klon |
ZR4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:200 - 1:400 |
Isotyp |
IgG |
Verdünnung |
Recombinant protein encoding human progesterone receptor 412-526 aa |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2023RT |
-
|
Host |
Rabbit |
Klon |
ZR290 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 1-200) of human PGR |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR290 |
1.0 ml |
Concentrate |
CE/IVD |
Z2728RL |
-
|
Host |
Rabbit |
Klon |
ZR290 |
Format |
r-t-u |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
gebrauchsfertig |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 1-200) of human PGR |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR290 |
7 ml |
r-t-u |
CE/IVD |
Z2728RP |
-
|
Host |
Rabbit |
Klon |
ZR290 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 1-200) of human PGR |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR290 |
0.5 ml |
Concentrate |
CE/IVD |
Z2728RS |
-
|
Host |
Rabbit |
Klon |
ZR290 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinomas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 1-200) of human PGR |
Lokalisation |
Nucleus |
Progesterone Receptor
|
Zeta Corporation |
ZR290 |
0.1 ml |
Concentrate |
CE/IVD |
Z2728RT |
-
|
Host |
Mouse |
Klon |
ZM203 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary gland. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human Prolactin (PRL) protein (around aa 63-201) |
Lokalisation |
Cytoplasm |
Prolactin
|
Zeta Corporation |
ZM203 |
1.0 ml |
Concentrate |
CE/IVD |
Z2523ML |
-
|
Host |
Mouse |
Klon |
ZM203 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary gland. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human Prolactin (PRL) protein (around aa 63-201) |
Lokalisation |
Cytoplasm |
Prolactin
|
Zeta Corporation |
ZM203 |
7 ml |
Ready-to-use |
CE/IVD |
Z2523MP |
-
|
Host |
Mouse |
Klon |
ZM203 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary gland. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human Prolactin (PRL) protein (around aa 63-201) |
Lokalisation |
Cytoplasm |
Prolactin
|
Zeta Corporation |
ZM203 |
0.5 ml |
Concentrate |
CE/IVD |
Z2523MS |
-
|
Host |
Mouse |
Klon |
ZM203 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary gland. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human Prolactin (PRL) protein (around aa 63-201) |
Lokalisation |
Cytoplasm |
Prolactin
|
Zeta Corporation |
ZM203 |
0.1 ml |
Concentrate |
CE/IVD |
Z2523MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pituitary Gland |
Verdünnung |
1:200 |
Isotyp |
Rabbit Ig |
Verdünnung |
Purified human prolactin |
Lokalisation |
Cytoplasm |
Prolactin (LTH, Luteotropic Hormone, Lactogenic Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
516-17492 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pituitary Gland |
Verdünnung |
1:200 |
Isotyp |
Rabbit Ig |
Verdünnung |
Purified human prolactin |
Lokalisation |
Cytoplasm |
Prolactin (LTH, Luteotropic Hormone, Lactogenic Hormone)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
516-17494 |
-
|
Host |
Mouse |
Klon |
XM26+LL002+4A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
ULTRA CC1 |
Positivkontrolle |
Normal prostate |
Verdünnung |
- |
Isotyp |
Mouse IgG1+IgG3+IgG 2a/kappa |
Lokalisation |
Cytoplasm and nucleus |
Prostate Cocktail, 2X (CK5+CK14+p63)
|
Biocare Medical |
XM26+LL002+4A4 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3206G |
-
|
Host |
Rabbit |
Klon |
ZR9 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal prostate or prostate carcinoma. |
Verdünnung |
1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptides to the N-terminus of human protein |
Lokalisation |
Cytoplasm |
Prostein (P501S)
|
Zeta Corporation |
ZR9 |
1.0 ml |
Concentrate |
CE/IVD |
Z2006RL |
-
|
Host |
Rabbit |
Klon |
ZR9 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal prostate or prostate carcinoma. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthesized peptides to the N-terminus of human protein |
Lokalisation |
Cytoplasm |
Prostein (P501S)
|
Zeta Corporation |
ZR9 |
7 ml |
Ready-to-use |
CE/IVD |
Z2006RP |
-
|
Host |
Rabbit |
Klon |
ZR9 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal prostate or prostate carcinoma. |
Verdünnung |
1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptides to the N-terminus of human protein |
Lokalisation |
Cytoplasm |
Prostein (P501S)
|
Zeta Corporation |
ZR9 |
0.5 ml |
Concentrate |
CE/IVD |
Z2006RS |
-
|
Host |
Rabbit |
Klon |
ZR9 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal prostate or prostate carcinoma. |
Verdünnung |
1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptides to the N-terminus of human protein |
Lokalisation |
Cytoplasm |
Prostein (P501S)
|
Zeta Corporation |
ZR9 |
0.1 ml |
Concentrate |
CE/IVD |
Z2006RT |
-
|
Host |
Mouse |
Klon |
31A3 |
Format |
Purified |
Methode |
P, WB, EL |
Vorbehandlung |
Citrate |
Verdünnung |
1:100 - 1:400 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native from brain |
Protein Gene Product 9.5 (PGP9.5, UCHL1)
|
Zytomed Systems GmbH |
31A3 |
200 µg |
Purified |
RUO |
616-0254 |
-
|
Host |
Mouse |
Klon |
13C4 |
Format |
Purified |
Methode |
P, WB, EL |
Vorbehandlung |
Citrate |
Verdünnung |
1:200 (P) |
Isotyp |
Mouse IgG2a |
Verdünnung |
Native from brain |
Protein Gene Product 9.5 (PGP9.5, UCHL1)
|
Zytomed Systems GmbH |
13C4 |
200 µl |
Purified |
RUO |
616-0255 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM160 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human UCHL1 protein |
Lokalisation |
Cytoplasm |
Protein Gene Product 9.5 (PGP9.5, UCHL1)
|
Zeta Corporation |
ZM160 |
1 ml |
Concentrate |
CE/IVD |
Z2473ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM160 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human brain. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human UCHL1 protein |
Lokalisation |
Cytoplasm |
Protein Gene Product 9.5 (PGP9.5, UCHL1)
|
Zeta Corporation |
ZM160 |
7 ml |
Ready-to-use |
CE/IVD |
Z2473MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM160 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human UCHL1 protein |
Lokalisation |
Cytoplasm |
Protein Gene Product 9.5 (PGP9.5, UCHL1)
|
Zeta Corporation |
ZM160 |
0.5 ml |
Concentrate |
CE/IVD |
Z2473MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM160 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human brain. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human UCHL1 protein |
Lokalisation |
Cytoplasm |
Protein Gene Product 9.5 (PGP9.5, UCHL1)
|
Zeta Corporation |
ZM160 |
0.1 ml |
Concentrate |
CE/IVD |
Z2473MT |
-
|
Host |
Rabbit |
Klon |
ZR232 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa150-250) of human KLK3 protein (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
PSA
|
Zeta Corporation |
ZR232 |
1 ml |
Concentrate |
RUO |
Z2710RL-R |
-
|